Nucleophosmin (NPM1) exon-12 gene mutations are the hallmark of a large acute myelogenous leukemia (AML) subgroup with normal karyotype, but their prognostic value in this AML subset has not yet been determined. We screened 401 AML patients with normal karyotype treated within the German AML Cooperative Group Protocol 99 (AMLCG99) study for NPM1 mutations. Results were related with partial tandem duplications within the MLL gene (MLL-PTD), Fms-like tyrosine kinase 3–length mutations (FLT3- LM), the tyrosine kinase domain of FLT3 (FLT3-TKD), NRAS, KIT, and CEBPAmutations and with clinical characteristics and outcome. NPM1 mutations were detected in 212 (52.9%) of 401 patients. Fourteen mutations, including 8 new variants, were identified. NPM1-mutated cases associated frequently with FLT3 mutations but rarely with other mutations. The NPM1- mutated group had a higher complete remission (CR) rate (70.5% vs 54.7%, P .003), a trend to a longer overall survival (OS; median 1012 vs 549 days, P .076), and significantly longer eventfree survival (EFS; median 428 vs 336 days; P .012). The favorable impact of NPM1 mutations on OS and EFS clearly emerged in the large group (264 [66.8%] of 395 cases) of normal-karyotype AML without FLT3-LM. This positive effect was lost in the presence of a concomitant FLT3-LM, since survival of the NPM1/ FLT3-LM double positive was similar to NPM1/FLT3-LM cases. In conclusion, this study demonstrates that NPM1/FLT3- LM mutations are an independent predictor for a favorable outcome in AML with normal karyotype. (Blood. 2005;106: 3733-3739)

Nucleophosmin gene mutations are predictors of favourable prognosis in acute myelogenous leukemia with a normal kayotype

MECUCCI, Cristina;MARTELLI, Massimo Fabrizio;FALINI, Brunangelo
2005

Abstract

Nucleophosmin (NPM1) exon-12 gene mutations are the hallmark of a large acute myelogenous leukemia (AML) subgroup with normal karyotype, but their prognostic value in this AML subset has not yet been determined. We screened 401 AML patients with normal karyotype treated within the German AML Cooperative Group Protocol 99 (AMLCG99) study for NPM1 mutations. Results were related with partial tandem duplications within the MLL gene (MLL-PTD), Fms-like tyrosine kinase 3–length mutations (FLT3- LM), the tyrosine kinase domain of FLT3 (FLT3-TKD), NRAS, KIT, and CEBPAmutations and with clinical characteristics and outcome. NPM1 mutations were detected in 212 (52.9%) of 401 patients. Fourteen mutations, including 8 new variants, were identified. NPM1-mutated cases associated frequently with FLT3 mutations but rarely with other mutations. The NPM1- mutated group had a higher complete remission (CR) rate (70.5% vs 54.7%, P .003), a trend to a longer overall survival (OS; median 1012 vs 549 days, P .076), and significantly longer eventfree survival (EFS; median 428 vs 336 days; P .012). The favorable impact of NPM1 mutations on OS and EFS clearly emerged in the large group (264 [66.8%] of 395 cases) of normal-karyotype AML without FLT3-LM. This positive effect was lost in the presence of a concomitant FLT3-LM, since survival of the NPM1/ FLT3-LM double positive was similar to NPM1/FLT3-LM cases. In conclusion, this study demonstrates that NPM1/FLT3- LM mutations are an independent predictor for a favorable outcome in AML with normal karyotype. (Blood. 2005;106: 3733-3739)
2005
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11391/151668
Citazioni
  • ???jsp.display-item.citation.pmc??? 161
  • Scopus 610
  • ???jsp.display-item.citation.isi??? ND
social impact